Press release

Business Wire1 week ago

Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK–(BUSINESS WIRE)–Halper Sadeh…
Read More »
Business Wire1 week ago

Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK–(BUSINESS WIRE)–Halper Sadeh…
Read More »
Press Release

Cision PR Newswire1 week ago
0

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

– 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following…
Read More »
Business Wire1 week ago

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

VIENNA–(BUSINESS WIRE)–#AOPHealth—AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers.…
Read More »
Press Release

Cision PR Newswire1 week ago
0

The 4th China International Supply Chain Expo Set for Beijing in June 2026

Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/ — The 4th China International Supply Chain Expo (“CISCE,”…
Read More »
Business Wire1 week ago

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and…
Read More »
Business Wire1 week ago

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of…
Read More »
Press Release

Cision PR Newswire1 week ago
0

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly,…
Read More »
Cision PR Newswire1 week ago
0

Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting

Anti-CD19 panCARTM program (ORN-252) demonstrated robust B cell depletion with significant reduction in anti-dsDNA titers in humanized lupus model Anti-BCMA…
Read More »
Business Wire1 week ago

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

– Benefits Seen Regardless of Eligibility for Previous Standard of Care of High-Dose Chemotherapy and Stem Cell Transplant for Second-Line…
Read More »

Previous page Next page